News
Data from clinical trials have indicated that PSA is prognostic for outcomes, but little is known about real-world trends.
Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate ...
If you or someone you know has received a prostate cancer diagnosis, here's where to start, what to ask and how to plan ...
June brought major prostate cancer updates, and CURE is sharing the latest FDA approvals, label expansions, and emerging data ...
An expert discusses how the PEACE III trial demonstrated that combining radium-223 with enzalutamide significantly improved ...
Prostate and colorectal cancers are two of the most common cancers affecting men in the U.S., and Black men face ...
"I'm so lucky to have people in my life who didn't hightail it out," actor and three-time cancer survivor Colin Egglesfield tells PEOPLE.
3d
Clinical Trials Arena on MSNFDA and EMA authorise AB Science’s Phase III trial of prostate cancer treatmentThe FDA and the EMA have authorised AB Science’s confirmatory Phase III Study AB22007 trial of masitinib for mCRPC.
J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...
Prostate cancer is the second most common cancer diagnosis in men. About one in eight men will be diagnosed with this disease during their lifetime. New Mexico Living spoke with Dr. Jose Avitia ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results